In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors

BRAF inhibitors have improved the treatment of advanced or metastatic melanoma in patients that harbor a BRAF(T1799A) mutation. Because of new insights into the role of aberrant glycosylation in drug resistance, we designed and studied three novel vemurafenib derivatives possessing pentose-associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Żołek, Teresa, Mazurek, Adam, Grudzinski, Ireneusz P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10343629/
https://www.ncbi.nlm.nih.gov/pubmed/37446932
http://dx.doi.org/10.3390/molecules28135273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10343629/
https://www.ncbi.nlm.nih.gov/pubmed/37446932
http://dx.doi.org/10.3390/molecules28135273

Ejemplares similares